ALLO (Allogene Therapeutics, Inc.) is a clinical-stage biotech company focused on allogeneic CAR-T therapies for cancer and autoimmune diseases. As of the latest close around May 20, 2026, the stock traded near $1.90 (down from recent highs near $2.30+ in mid-May, following a sharp drop after an April offering and volatility). $ALLO

Recent Technical Analysis SummaryTrend: Short-term bearish. The stock has declined from ~$2.33 (May 13) to ~$1.90, breaking below recent supports. It remains well above its longer-term 200-day SMA (~$1.66, bullish on a very long horizon) but below shorter-term moving averages (e.g., 50-day around $2.3+).

Momentum Indicators: Many sources show Strong Sell or Sell signals on daily/weekly timeframes (e.g., multiple moving averages in sell territory, RSI in neutral-to-oversold but not strongly rebounding).

Key Levels:Resistance: ~$2.00–$2.13, then higher at $2.30–$2.40.

Support: ~$1.85–$1.90 (recent lows), then down toward $1.66 or lower.

Volume: Elevated during the recent decline and April events (offering, trial news).

Broader Context: Biotech stocks are volatile and news-driven (clinical trial updates, funding). Recent positive trial data (e.g., ALPHA3) contrasts with dilution from offerings and cash burn. Analyst consensus is generally Moderate Buy with high long-term price targets (~$8+ average, very optimistic vs. current levels), but near-term technicals are weak.

Here is a generated chart of recent daily closes (based on available historical data up to ~May 20, 2026):

More Realistic Scenario Outlook (my synthesis, not a forecast): Bullish case (if positive news/catalyst or oversold bounce): Rebound toward $2.00–$2.20 on volume, testing resistance.

Base case (continuation of recent pressure): Range-bound or mild decline to $1.70–$1.90.

Bearish case: Break below $1.85 toward $1.60s if no positive catalysts.